Emergent BioSolutions Stock Price and Value Analysis

Should you buy Emergent BioSolutions stock? (NYSE:EBS). Let's see how it does in our automated value investing analysis system.

EBS Free Cash Flow Trend

Free Cash Flow trendline for EBS
Free Cash Flow trendline for Emergent BioSolutions

Based on historical returns, we believe that Emergent BioSolutions can grow its free cash at a rate of about 1%. That's positive!

  • This company is solid.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the EBS Numbers

EBS Price
(Emergent BioSolutions stock price per share)
[?] EBS Fair Price
(based on intrinsic value)
[?] EBS Safety Price (based on a variable margin of safety) $15.41
[?] PE Ratio versus Sector 166% higher than other Healthcare stocks
[?] PE Ratio versus Industry 6% lower than other Biotechnology stocks
[?] Cash Yield 1.57%
[?] Free Cash Flow Jitter 1866%

Is Emergent BioSolutions Stock on Sale?

We believe that Emergent BioSolutions may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Emergent BioSolutions looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy EBS Stock?

Does Emergent BioSolutions have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.